Pursuant to Second proviso to Regulation 30(6) and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Amerise Biosciences (formerly Amradeep Industries) reported un-audited results for Q2 FY26 and H1 FY26 on November 5, 2025. Revenue from operations is nil across all periods, with total income coming only from 'other income' of Rs 6.75 lakhs in Q2 and Rs 13.11 lakhs in H1 FY26. Total expenses stood at Rs 10.98 lakhs (Q2) and Rs 18.15 lakhs (H1), resulting in a net loss of Rs 4.23 lakhs for Q2 and Rs 5.04 lakhs for H1 FY26, compared to a loss of Rs 8.24 lakhs in the same period last year. The company reported negative other equity of Rs (127.75) lakhs as on September 30, 2025, indicating accumulated losses. Operating cash flow was positive at Rs 7.02 lakhs. Auditor Bipin & Co. issued a clean (unqualified) limited review report.
The company continues to report zero core operating revenue and is running at a loss, with negative reserves (other equity) eroding shareholder value. However, losses have narrowed compared to last year and operating cash flow improved, but investors should note the absence of any visible revenue-generating business activity.